Total Payments
$217,105
2024 Payments
$48,525
Companies
20
Transactions
250
Medicare Patients
10,347
Medicare Billing
$5.6M
Payment Breakdown by Category
Other$112,505 (51.8%)
Consulting$70,953 (32.7%)
Travel$24,945 (11.5%)
Food & Beverage$7,289 (3.4%)
Research$1,362 (0.6%)
Education$51.04 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $107,955 | 27 | 49.7% |
| Consulting Fee | $70,953 | 28 | 32.7% |
| Travel and Lodging | $24,945 | 92 | 11.5% |
| Food and Beverage | $7,289 | 95 | 3.4% |
| Honoraria | $4,550 | 1 | 2.1% |
| Unspecified | $1,362 | 4 | 0.6% |
| Education | $51.04 | 3 | 0.0% |
Payments by Type
General
$215,742
246 transactions
Research
$1,362
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $53,473 | 59 | $0 (2024) |
| GENZYME CORPORATION | $40,926 | 41 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $36,600 | 38 | $0 (2024) |
| Coherus Biosciences Inc. | $31,911 | 26 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $19,948 | 27 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $9,970 | 9 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $9,209 | 8 | $0 (2019) |
| Novocure Inc. | $6,356 | 14 | $0 (2024) |
| Heron Therapeutics, Inc. | $2,901 | 4 | $0 (2018) |
| Daiichi Sankyo Inc. | $2,260 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,525 | 59 | Coherus Biosciences Inc. ($31,911) |
| 2023 | $14,442 | 22 | Novocure Inc. ($6,006) |
| 2022 | $2,706 | 6 | GENZYME CORPORATION ($2,416) |
| 2021 | $13,093 | 8 | Regeneron Healthcare Solutions, Inc. ($5,240) |
| 2020 | $3,368 | 3 | AstraZeneca Pharmaceuticals LP ($2,055) |
| 2019 | $40,559 | 39 | GENZYME CORPORATION ($17,283) |
| 2018 | $78,588 | 97 | Regeneron Healthcare Solutions, Inc. ($33,012) |
| 2017 | $15,825 | 16 | E.R. Squibb & Sons, L.L.C. ($15,435) |
All Payment Transactions
250 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,286.00 | General |
| 12/10/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $168.71 | General |
| Category: Oncology | ||||||
| 11/29/2024 | Regeneron Healthcare Solutions, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $881.00 | General |
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $303.97 | General |
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | — | Food and Beverage | In-kind items and services | $4.00 | General |
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | — | Food and Beverage | In-kind items and services | $108.99 | General |
| 11/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $59.99 | General |
| 11/12/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $112.32 | General |
| Category: Oncology | ||||||
| 11/09/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $154.98 | General |
| 10/25/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,762.00 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,762.00 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,541.75 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $881.00 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $440.50 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $45.95 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Coherus Biosciences Inc. | LOQTORZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,412.50 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Coherus Biosciences Inc. | LOQTORZI (Biological) | Travel and Lodging | Cash or cash equivalent | $384.58 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Coherus Biosciences Inc. | LOQTORZI (Biological) | Travel and Lodging | In-kind items and services | $240.34 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Coherus Biosciences Inc. | LOQTORZI (Biological) | Food and Beverage | In-kind items and services | $108.46 | General |
| Category: Oncology | ||||||
| 08/21/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $15.33 | General |
| Category: Oncology | ||||||
| 08/19/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/14/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Oncology | ||||||
| 07/14/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $17.62 | General |
| 06/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $118.45 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $142.27 | General |
| Category: Granulocyte colony stimulating factor | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | AbbVie Inc. | $92.34 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 55 | 2,490 | 62,267 | $6.6M | $1.2M |
| 2022 | 43 | 1,926 | 40,225 | $4.6M | $955,896 |
| 2021 | 58 | 2,794 | 70,938 | $6.5M | $1.5M |
| 2020 | 69 | 3,137 | 90,872 | $9.5M | $2.0M |
Total Patients
10,347
Total Services
264,302
Medicare Billing
$5.6M
Procedure Codes
225
All Medicare Procedures & Services
225 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 31 | 8,802 | $1.9M | $373,365 | 19.9% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 43 | 9,540 | $1.9M | $361,023 | 18.8% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 11 | 4,800 | $579,388 | $114,423 | 19.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 184 | 376 | $197,400 | $50,200 | 25.4% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 17 | 1,140 | $157,844 | $40,815 | 25.9% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 15 | 4,000 | $208,757 | $38,074 | 18.2% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 20 | 1,620 | $320,148 | $35,647 | 11.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 15 | 1,560 | $144,779 | $29,221 | 20.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 243 | 285 | $208,620 | $28,619 | 13.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 192 | 278 | $93,130 | $25,398 | 27.3% |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Office | 2023 | 13 | 920 | $172,554 | $20,101 | 11.6% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 16 | 7,060 | $74,830 | $16,530 | 22.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 83 | 83 | $61,005 | $13,787 | 22.6% |
| Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | Office | 2023 | 14 | 624 | $100,735 | $11,670 | 11.6% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 19 | 88 | $33,072 | $11,111 | 33.6% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 11 | 132 | $124,423 | $10,841 | 8.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 55 | 86 | $20,124 | $4,835 | 24.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 173 | 396 | $48,708 | $4,692 | 9.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 73 | 95 | $36,860 | $4,677 | 12.7% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 23 | 27 | $22,950 | $3,486 | 15.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 25 | 31 | $5,425 | $2,973 | 54.8% |
| J9070 | Cyclophosphamide, 100 mg | Office | 2023 | 11 | 174 | $17,067 | $2,802 | 16.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 70 | 125 | $22,625 | $2,732 | 12.1% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 107 | 117 | $14,625 | $2,398 | 16.4% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 12 | 280 | $9,777 | $2,142 | 21.9% |
About Dr. Panayiotis Savvides, MD
Dr. Panayiotis Savvides, MD is a Medical Oncology healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1831115385.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Panayiotis Savvides, MD has received a total of $217,105 in payments from pharmaceutical and medical device companies, with $48,525 received in 2024. These payments were reported across 250 transactions from 20 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($107,955).
As a Medicare-enrolled provider, Savvides has provided services to 10,347 Medicare beneficiaries, totaling 264,302 services with total Medicare billing of $5.6M. Data is available for 4 years (2020–2023), covering 225 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Phoenix, AZ
- Active Since 07/15/2006
- Last Updated 04/29/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1831115385
Products in Payments
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $33,012
- LOQTORZI (Biological) $31,601
- LIBTAYO (Drug) $31,327
- LIBTAYO (Biological) $25,874
- OPDIVO (Biological) $25,226
- TAGRISSO (Drug) $14,763
- Non-Covered $6,284
- Vitrakvi (Drug) $2,925
- SUSTOL (Drug) $2,901
- ZEPZELCA (Drug) $1,313
- ELREXFIO (Drug) $1,270
- NO PRODUCT DISCUSSED (Drug) $1,177
- Optune Lua (NovoTTF-200T) (Device) $350.73
- Udenyca (Biological) $309.35
- ZYKADIA (Drug) $171.63
- RYBREVANT (Drug) $166.18
- KRAZATI (Drug) $116.34
- Zelboraf (Biological) $114.31
- LORBRENA (Drug) $51.04
- DOPTELET (Drug) $26.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Phoenix
Dr. Jason Salganick, Md, MD
Medical Oncology — Payments: $1.9M
Medical Oncology $1.9M
Mazen Khattab, Md, MD
Medical Oncology — Payments: $226,385
Medical Oncology $226,385
Amber Flaherty, M.d, M.D
Medical Oncology — Payments: $41,476
Medical Oncology $41,476
Tania Cortas, Md, MD
Medical Oncology — Payments: $36,718
Medical Oncology $36,718
Waqas Arslan, M.d, M.D
Medical Oncology — Payments: $34,523
Medical Oncology $34,523
Dr. Amir Azadi, M.d, M.D
Medical Oncology — Payments: $23,762
Medical Oncology $23,762